Karima Schwab et al., 2022-06-13: Alpha-synuclein transgenic mouse study in which hydromethylthionine normalised NMDA receptor subunit ratios and mGluR5 levels, which the authors read as evidence it inhibits pathological alpha-synuclein aggregation.
Our results confirm that HMTM acts in the L62 mouse model of PD as an inhibitor of pathological aggregation of synuclein
Abstract
Karima Schwab et al., 2022-06-13: Alpha-synuclein transgenic mouse study in which hydromethylthionine normalised NMDA receptor subunit ratios and mGluR5 levels, which the authors read as evidence it inhibits pathological alpha-synuclein aggregation. Animal study in transgenic h-alpha-synL62 mice (N not in abstract). Country: Germany and United Kingdom (Charite Berlin; University of Aberdeen/TauRx). Dose: hydromethylthionine mesylate, oral in drinking water per the full text (dose not in abstract). Route: oral. Funder: 'Research Support, Non-U.S. Gov't' (TauRx). Conflicts: Wischik and Harrington are TauRx-affiliated – verifier should read the disclosure. Comparator: wild-type mice and vehicle-treated transgenics; MTEP and memantine combination arms. Bearing note: this is the alpha-synuclein evidence, and it is indirect – receptor normalisation, not a direct measurement of alpha-synuclein aggregate load in the abstract. Study type: animal.
